Related by context. All words. (Click for frequent words.) 79 chemotherapy regimen 76 chemotherapies 75 chemotherapeutic regimens 72 standard chemotherapy regimens 71 treatment regimens 71 docetaxel chemotherapy 71 cytotoxic chemotherapy 70 cisplatin 70 etoposide 69 gemcitabine 69 rituximab 69 chemotherapeutic agents 68 metastatic colorectal cancer 68 docetaxel 68 chemoradiation 68 bortezomib 67 HER2 positive metastatic breast 67 cyclophosphamide 67 irinotecan 67 adjuvant therapy 66 chemotherapy 66 neoadjuvant chemotherapy 66 dasatinib 66 fluorouracil 66 CHOP chemotherapy 66 taxanes 66 cetuximab 66 dacarbazine 66 gemcitabine chemotherapy 66 anthracycline 66 NSCLC 66 5 FU 65 DMARDs 65 FOLFIRI 65 advanced NSCLC 65 carboplatin 65 gemcitabine Gemzar 65 taxane therapy 65 oxaliplatin 65 trastuzumab 65 heavily pretreated patients 65 imatinib 65 mycophenolate mofetil 65 therapeutic regimens 65 regimens 65 tyrosine kinase inhibitors 65 alkylating agents 65 chemotherapeutic 64 temozolomide 64 antiretroviral regimens 64 chlorambucil 64 taxane chemotherapy 64 bevacizumab Avastin 64 fludarabine 64 5 fluorouracil 64 sunitinib 64 dosing schedules 64 idarubicin 64 chemoradiotherapy 64 mitoxantrone 64 carboplatin paclitaxel 64 imatinib Gleevec 64 topotecan 64 indolent NHL 64 adjuvant chemotherapy 64 metastatic renal cell carcinoma 64 hormonal therapy 63 hormonal therapies 63 bendamustine 63 bevacizumab 63 standard chemotherapy regimen 63 chemotherapeutic agent 63 bevacizumab Avastin ® 63 DMARD therapy 63 anthracyclines 63 gefitinib 63 Doxil ® 63 erlotinib 63 sorafenib Nexavar 63 pegylated interferon 63 paclitaxel Taxol 63 sorafenib Nexavar ® 63 dosing regimens 63 trastuzumab Herceptin ® 63 vinorelbine 63 resistant ovarian cancer 63 trans retinoic acid ATRA 63 5FU 63 platinum refractory 63 cisplatin chemotherapy 63 relapsed refractory 63 superficial bladder cancer 63 sorafenib 62 taxane 62 pegylated liposomal doxorubicin 62 metastatic CRC 62 immunosuppressive regimens 62 chemotherapeutic drugs 62 FOLFOX 62 postoperative chemotherapy 62 HAART regimen 62 mCRC 62 DMARD 62 alkylating agent 62 mRCC 62 PegIFN RBV 62 ribavirin therapy 62 docetaxel Taxotere 62 dosage regimens 62 tamoxifen therapy 62 Fludara 62 differentiated thyroid 62 erlotinib Tarceva ® 62 relapsed ovarian cancer 62 mCRC patients 62 overlapping toxicities 62 pegfilgrastim 62 methotrexate 62 pancreatic adenocarcinoma 62 cytarabine 62 chemo radiotherapy 62 cytotoxic therapy 62 follicular NHL 62 dose regimens 62 follicular lymphoma 62 immunosuppressive agents 62 metastatic RCC 62 chemotherapy docetaxel 61 chemotherapeutics 61 xenograft models 61 pemetrexed 61 temsirolimus 61 irinotecan chemotherapy 61 gemcitabine carboplatin 61 lenalidomide Revlimid R 61 decitabine 61 brain metastases 61 daunorubicin 61 heavily pretreated 61 infliximab 61 gefitinib Iressa 61 interferon therapy 61 KRAS status 61 pertuzumab 61 Cisplatin 61 colorectal liver metastases 61 imatinib therapy 61 disease modifying antirheumatic 61 NRTIs 61 fluoropyrimidine 61 antiretroviral regimen 61 nilotinib 61 azathioprine 61 Taxotere ® 61 chemotherapeutic regimen 61 metastatic colon cancer 61 recurrent GBM 61 doxorubicin 61 TTF Therapy 61 cisplatin carboplatin 61 ribavirin RBV 61 HAART regimens 61 neoadjuvant therapy 61 liposomal doxorubicin 61 fulvestrant 61 remission induction 60 nab paclitaxel 60 arsenic trioxide 60 monotherapy 60 refractory NSCLC 60 FOLFOX4 60 pegylated interferon alfa 60 lapatinib Tykerb 60 Doxorubicin 60 resectable 60 paclitaxel carboplatin 60 SCCHN 60 Pemetrexed 60 concurrent chemoradiation 60 capecitabine 60 follicular non 60 anticancer agents 60 VELCADE 60 lamivudine 60 recurrent NSCLC 60 antiviral therapy 60 chronic lymphocytic leukemia CLL 60 non squamous NSCLC 60 dose cytarabine 60 Platinol ® cisplatin 60 virological failure 60 interferon alfa 60 Fludarabine 60 TKIs 60 preoperative chemotherapy 60 Velcade bortezomib 60 paclitaxel Taxol R 60 azacitidine 60 GnRH agonists 60 panitumumab 60 refractory multiple myeloma 60 EGFR inhibitors 60 protease inhibitor PI 60 TACE 60 5-FU/LV 60 hormone refractory prostate cancer 60 biologic therapy 60 paclitaxel Taxol ® 60 ABVD 60 trastuzumab Herceptin 60 cytoreduction 59 unresectable 59 pomalidomide 59 peginterferon 59 adriamycin 59 paclitaxel 59 mitomycin 59 neoadjuvant 59 docetaxel Taxotere R 59 malignant pleural mesothelioma 59 vandetanib 59 dasatinib Sprycel 59 low dose cytarabine 59 antiplatelet therapy 59 interferon alfa 2a 59 antibiotic regimens 59 interferon ribavirin 59 doxorubicin HCl liposome injection 59 relapsed MM 59 methotrexate therapy 59 epirubicin 59 intravenous bisphosphonates 59 APTIVUS r 59 antihypertensive agents 59 complete remissions 59 dasatinib Sprycel ® 59 enzastaurin 59 metastatic SCCHN 59 relapsed 59 trabectedin 59 metastatic melanoma 59 adalimumab 59 FOLFOX chemotherapy 59 cytotoxic agents 59 temozolomide TMZ 59 ixabepilone 59 radiochemotherapy 59 microwave hyperthermia 59 Gemcitabine 59 BEACOPP 59 tyrosine kinase inhibitors TKIs 59 imetelstat 59 leucovorin 59 achieve sustained virologic 59 adjuvant radiation 59 metastatic breast cancer 59 vinca alkaloids 59 thalidomide Thalomid 59 anti TNF 59 Ph + ALL 59 docetaxel Taxotere ® 59 LHRH analogues 59 curative resection 59 CANCIDAS 59 #mg/m# [002] 59 fallopian tube carcinoma 59 pegylated interferon alfa 2a 59 Trastuzumab 59 radiation chemoradiation 59 radiation therapy SBRT 59 INTELENCE 59 DLBCL 59 virologic failure 59 CVP chemotherapy 58 neoadjuvant treatment 58 tamoxifen 58 liver metastases 58 HRPC 58 dexamethasone Decadron 58 DOXIL 58 androgen deprivation 58 rituximab Rituxan 58 panobinostat 58 hematological cancers 58 prior chemotherapy regimens 58 anti angiogenic agents 58 cetuximab Erbitux ® 58 chemotherapy cisplatin 58 cediranib 58 oblimersen 58 hematologic malignancies 58 Allovectin 7 ® 58 boosted protease inhibitor 58 HGS ETR1 58 surgical debulking 58 interferon 58 lymph node dissection 58 anticancer treatments 58 refractory AML 58 glioblastoma multiforme GBM 58 adverse cytogenetics 58 systemic ALCL 58 NNRTIs 58 follicular lymphoma FL 58 anti leukemic 58 anthracycline taxane 58 carfilzomib 58 Taxotere R 58 recurrent ovarian cancer 58 intraperitoneal chemotherapy 58 multiple myeloma 58 TKI therapy 58 CLL 58 cytarabine daunorubicin 58 ritonavir boosted protease inhibitor 58 NNRTI 58 peg IFN 58 histologies 58 hepatic metastases 58 Zevalin consolidation 58 TNF inhibitor 58 T#I mutation 58 external beam radiotherapy 58 eribulin 58 antihypertensive therapy 58 galiximab 58 anticancer therapies 58 dose cohorts 58 relapsed SCLC 58 previously untreated follicular 58 plus ribavirin 58 Platinol 58 chemotherapy gemcitabine 58 ritonavir boosted 58 allogeneic SCT 58 HGS# 58 Doxil 58 colorectal cancer liver metastases 58 XELOX 58 Bortezomib 58 lymphomas 58 imatinib resistant 58 clinically localized prostate 58 Revlimid lenalidomide 58 oral clodronate 58 Paraplatin ® carboplatin 58 stage IIIB 58 epithelial tumors 58 Gleevec imatinib 58 amrubicin 58 PREZISTA r 58 therapies 58 Vectibix 58 FOLFOX6 58 infusional 5-FU/LV 58 metastatic malignant melanoma 58 Pegasys ® 58 histological subtypes 57 pazopanib 57 hematologic 57 KRAS wild 57 antitumor activity 57 antidepressant therapy 57 HER2 positive breast cancer 57 Cytoxan 57 IMGN# 57 lenalidomide 57 immunosuppressant 57 myeloablative 57 cytoreductive surgery 57 Cloretazine 57 anticancer therapy 57 dexamethasone 57 refractory CLL 57 5 FU leucovorin 57 solid tumors 57 leukemia CLL 57 adecatumumab 57 mapatumumab 57 exemestane 57 raltegravir 57 prostate cancer HRPC 57 seliciclib 57 locoregional 57 VICTRELIS 57 lenalidomide dexamethasone 57 interferon IFN 57 cidofovir 57 relapsed refractory multiple myeloma 57 EGFR expressing 57 Fludara ® 57 TNF inhibitors 57 Adjuvant chemotherapy 57 cetuximab Erbitux R 57 intra arterial chemotherapy 57 sunitinib malate 57 axitinib 57 Pegylated Interferon 57 cilengitide 57 bleomycin 57 vincristine 57 endocrine therapy 57 Cremophor 57 HSCT 57 thrombolytic agents 57 elacytarabine 57 BRAF mutation 57 receptor tyrosine kinase inhibitor 57 metastatic HRPC 57 vorinostat 57 gastrointestinal stromal tumor GIST 57 ribavirin 57 durable remissions 57 VIDAZA 57 Mylotarg 57 refractory ovarian cancer 57 Erlotinib 57 care regimens CCR 57 lupus nephritis 57 Anthracycline 57 immunomodulatory therapy 57 PARP inhibitors 57 Pixantrone 57 Tarceva erlotinib 57 metastatic hormone refractory 57 MMP inhibitors 57 glioblastoma 57 interferon alfa 2b 57 nucleoside analogs 57 EGFR mutation 57 dose dexamethasone 57 Targretin 57 Peg IFN 57 refractory CTCL 57 EGFR expressing mCRC 57 imatinib mesylate 57 gemcitabine Gemzar ® 57 adjuvant tamoxifen 57 infliximab Remicade 57 IV NSCLC 57 Taxotere 57 melphalan prednisone 57 dose regimen 57 metastatic kidney 57 Gleevec resistant 57 peginterferon alfa 2a 57 induction regimen 57 Amrubicin 57 cisplatin gemcitabine 57 6 mercaptopurine 57 intraperitoneal therapy 57 rituximab Rituxan ® 56 CCyR 56 TORISEL 56 isoniazid 56 antibiotic therapy 56 OncoVEX GM CSF 56 ganetespib 56 free survival PFS 56 B CLL 56 Vectibix monotherapy 56 concomitant medications 56 toxicities 56 debulking surgery 56 trans retinoic acid 56 paclitaxel chemotherapy 56 Xanafide 56 imatinib Gleevec ® 56 cytotoxic 56 leukemia AML 56 visilizumab 56 FOLFIRINOX 56 Platinol ® 56 myelosuppression 56 partial remissions 56 Taxotere chemotherapy 56 FOLFOX regimen 56 darunavir ritonavir 56 Carboplatin 56 trastuzumab Herceptin R 56 KRAS mutations occur 56 grade gliomas 56 mg/m2 dose 56 Irinotecan 56 pegylated interferon alpha 56 chemotherapeutic drug 56 anthracycline containing 56 metastatic castration resistant 56 nilotinib Tasigna ® 56 letrozole Femara 56 diagnosed multiple myeloma 56 Mitoxantrone 56 APTIVUS 56 SUTENT 56 BEXXAR 56 stage IIIB IV 56 gemcitabine cisplatin 56 pegylated interferons 56 DMARDS 56 lapatinib 56 Gemzar ® 56 IV metastatic melanoma 56 corticosteroid therapy 56 Carfilzomib 56 radiation therapy 56 olaparib 56 #mg/m# [001] 56 Xcytrin 56 Bevacizumab 56 anastrozole 56 immunosuppressive drugs 56 plus dexamethasone 56 adjuvant therapies 56 antiangiogenic therapy 56 OPAXIO 56 cyclophosphamide Cytoxan 56 dacarbazine chemotherapy 56 refractory chronic myeloid 56 ceftriaxone 56 Neulasta ® 56 neratinib 56 capecitabine Xeloda 56 HAART 56 FOLPI 56 CsA 56 melphalan 56 surrogate endpoint 56 irinotecan containing 56 hyperthermia therapy 56 Telintra 56 virologic response 56 proteasome inhibitors 56 EGFR TKI 56 molecularly targeted 56 EGFR mutations 56 malignancies 56 cytogenetic response 56 HER2 negative 56 iniparib 56 VELCADE melphalan 56 paclitaxel cisplatin 56 myelodysplastic syndrome MDS 56 bortezomib Velcade R 56 cyclophosphamide doxorubicin vincristine 56 tyrosine kinase inhibitor 56 acute leukemias 56 evaluating REVLIMID 56 abiraterone acetate 56 fibrinolytic 56 ponatinib 56 cardiac toxicity 56 hormone receptor positive 56 MGd 56 vincristine doxorubicin 56 relapsed refractory ALL 56 Gleevec imatinib mesylate 56 MabCampath 56 CA4P 56 ZEVALIN 56 tocilizumab 56 induce remission 56 PEGINTRON 56 mTOR inhibitors 56 eribulin mesylate 56 ELOXATIN 56 BEXXAR therapeutic regimen 56 Paraplatin ® 55 Copegus ribavirin 55 recurrent metastatic 55 EGFR tyrosine kinase inhibitors 55 cytogenetic responses 55 immunosuppressive therapies 55 Panzem R NCD 55 pegylated alpha interferon 55 recurrent glioblastoma multiforme 55 dacarbazine DTIC 55 cell lung cancer 55 glufosfamide 55 PSADT 55 recurrent prostate cancer 55 HER2 + 55 BCG refractory 55 potentially hepatotoxic 55 azacytidine 55 cystectomy 55 relapsed AML 55 bortezomib Velcade 55 non squamous 55 Rituximab 55 goserelin 55 drug DMARD 55 warfarin therapy 55 Sunitinib 55 antihypertensive drugs 55 platelet inhibitor 55 farletuzumab 55 Sorafenib 55 neurologic progression 55 nevirapine Viramune 55 adjuvant radiotherapy 55 erlotinib Tarceva 55 tumor regression 55 calcineurin inhibitors 55 Hodgkin lymphoma NHL 55 aflibercept VEGF Trap 55 metastatic CRPC 55 mitoxantrone chemotherapy 55 tigecycline 55 imatinib mesylate Gleevec 55 invasive candidiasis 55 metastatic disease 55 tipranavir 55 Navelbine ® 55 Velcade 55 infusional 55 corticosteroids 55 Sutent sunitinib 55 virological response 55 radiofrequency ablation RFA 55 metastatic GIST 55 PREZISTA rtv 55 REVLIMID 55 androgen deprivation therapy 55 doublet chemotherapy 55 TNF antagonist 55 locoregional recurrence 55 Herceptin trastuzumab 55 stavudine 55 CHOP cyclophosphamide doxorubicin vincristine 55 bisphosphonate therapy 55 amphotericin B 55 castration resistant prostate cancer 55 FluCAM 55 metastatic lung cancer 55 alvespimycin 55 medically inoperable 55 prednisone CHOP 55 hypomethylating agents 55 acute myeloid leukemia AML 55 T DM1 55 Bezielle 55 EBRT 55 sipuleucel T 55 metastatic NSCLC 55 renal tumors 55 PXD# 55 cranial irradiation 55 genotypic resistance 55 zoledronic acid 55 Combination therapy 55 Camptosar 55 recurrent glioblastoma 55 acute promyelocytic leukemia APL 55 subgroup analyzes 55 dose escalation 55 chronic myeloid leukemia CML 55 alfa 2a 55 androgen ablation 55 platelet transfusions 55 myeloma 55 CoFactor 55 acute GvHD 55 VFEND 55 relapsed multiple myeloma 55 amoxicillin clavulanate 55 CLL SLL 55 clofarabine 55 fluvastatin 55 IMC A# 55 lipid lowering therapies 55 allogeneic stem cell 55 enfuvirtide 55 assessing T DM1 55 autologous stem cell 55 MEK inhibitors 55 hepatocellular carcinoma HCC 55 ara C 55 EGFR TKIs 55 tamoxifen Nolvadex ® 55 chemoradiation therapy 55 GEMZAR 55 operable breast cancer 55 YONDELIS 55 BAY #-# 55 Ribavirin 55 Perifosine 55 antifungal therapy 55 xanthine oxidase inhibitor 55 HER2 positive 55 tumor shrinkage 55 Alemtuzumab 55 Metastatic Colorectal Cancer 55 pneumonectomy 55 cyclophosphamide methotrexate 55 Methotrexate 55 myelodysplastic syndromes MDS 55 breast carcinoma 55 pancreatic NET 55 gastrointestinal stromal tumors GIST 55 sustained virologic response 55 AMN# [001] 55 Chemotherapy 55 immunosuppressive medications 55 telaprevir dosed 55 Kantarjian 55 nucleoside analogues 55 L asparaginase 55 myelosuppressive 55 drugs DMARDs 55 MyVax R 55 placebo dexamethasone 55 acute myelogenous leukemia AML 55 estramustine 55 doxorubicin cyclophosphamide 55 arsenic trioxide ATO 55 viral kinetics 55 AGILECT R 54 Flu Cy 54 DCVax ® Brain 54 plasma uric acid 54 Gefitinib 54 ERBITUX 54 milatuzumab 54 caspofungin 54 gastrointestinal stromal tumors 54 certolizumab 54 Camptosar ® 54 cytotoxics 54 uric acid lowering 54 CYT# potent vascular disrupting 54 Pertuzumab 54 letrozole 54 HCV infection 54 ELACYT 54 prostate cancer CRPC 54 cell lymphoma CTCL 54 CBLC# 54 anti angiogenic drugs 54 aromatase inhibitor 54 irinotecan doxorubicin oxaliplatin paclitaxel 54 stavudine d4T 54 ethambutol 54 advanced unresectable 54 diagnosed glioblastoma multiforme 54 Tamoxifen 54 Bcr Abl inhibitors 54 cabazitaxel 54 TNF antagonists 54 Oxaliplatin 54 sustained virological response 54 Surgical resection 54 3TC lamivudine Epivir 54 hematological 54 HCV genotype 1 54 figitumumab 54 splenectomized patients 54 rindopepimut 54 radiotherapy RT 54 untreated CLL 54 Cetuximab 54 K ras mutations 54 cetuximab Erbitux 54 doxorubicin docetaxel 54 renal cell carcinoma 54 pegylated interferon alfa 2b 54 cranial radiation 54 ZYVOX 54 Capecitabine 54 peginterferon alfa 2a Pegasys 54 depsipeptide 54 protease inhibitor 54 monoclonal antibody therapies 54 EOquin TM 54 pyrazinamide 54 voriconazole 54 Response Evaluation Criteria 54 chronic GVHD 54 ISTODAX 54 APTIVUS R 54 paricalcitol 54 complete cytogenetic 54 posaconazole 54 entecavir 54 antithrombotic therapy 54 palliative radiotherapy 54 anthracyclines taxanes 54 antiretroviral therapy 54 statin therapy 54 NSTE ACS 54 Torisel 54 motesanib 54 Halaven 54 darunavir 54 inhibitor RG# 54 allogeneic transplant 54 intravesical 54 exemestane Aromasin 54 DAPT 54 treatments 54 5-fluorouracil/leucovorin 54 TRISENOX 54 ALIMTA 54 ibritumomab tiuxetan 54 serous ovarian cancer 54 Zolinza 54 Revlimid 54 AVASTIN 54 fosamprenavir 54 FOLOTYN 54 basal cell carcinoma BCC 54 relapsed CLL 54 Corticosteroids 54 ofatumumab 54 BRAF inhibitor 54 unresectable stage 54 mycophenolate mofetil MMF 54 NRTI 54 Radical prostatectomy 54 plus gemcitabine 54 antiretroviral therapies 54 CMV disease 54 PLX# 54 FIRMAGON 54 lintuzumab 54 papillary renal cell carcinoma 54 RECIST criteria 54 evaluable patients 54 antimetabolite 54 adefovir 54 metastatic renal cell 54 relapsing remitting 54 HBeAg positive patients 54 peginterferon alfa 54 SPRYCEL 54 antiangiogenic agents 54 receiving highly emetogenic 54 HER2 positive cancers 54 hematologic toxicity 54 conventional chemotherapies 54 non metastatic osteosarcoma 54 untreated AML 54 chemopreventive agents 54 nucleoside reverse transcriptase inhibitor 54 relapsing multiple sclerosis 54 nucleoside analogue 54 clopidogrel 54 Aromasin 54 Rituxan 54 metastatic malignant 54 microtubule inhibitor 54 baseline LDH 54 Imatinib 54 nonmyeloablative 54 Dasatinib 54 leflunomide 54 efavirenz Sustiva 54 5 fluorouracil leucovorin 54 romiplostim 54 abatacept 54 PSMA ADC 54 localized prostate cancer 54 unfractionated heparin 54 Traficet EN 54 tanespimycin 54 radioimmunotherapy 54 rFVIIa 54 evaluating Xcytrin 54 alkylating 54 Taxotere docetaxel 54 peginterferon alfa 2b 54 VEGF inhibitors 54 Taxol ® 54 hematological malignancies 54 sunitinib Sutent 54 metastatic pancreatic cancer 54 receiving VICTRELIS 54 anthracycline therapy 54 endometrial carcinoma 54 Elitek 54 oral corticosteroids 54 perifosine 54 ifosfamide 54 gemtuzumab ozogamicin 54 mg/m2 54 remission CR 54 ZOLINZA 54 radical nephrectomy 54 leukemia APL 54 MGCD# [001] 54 zalutumumab 54 bone metastases 54 peg interferon 54 chronic myelogenous leukemia CML 54 vancomycin 54 nonresponders 54 Anthracyclines 54 prednisone prednisolone 54 KRAS mutant tumors 54 low dose dexamethasone 54 Hycamtin 54 MYLOTARG 54 FOLFIRI alone 54 axillary dissection 54 REVLIMID ® 54 mcg albinterferon alfa 2b 54 grade cervical intraepithelial 54 nonsmall cell lung cancer 54 familial amyloidotic polyneuropathy FAP 54 Vidaza ® 54 anti angiogenic therapy 54 capecitabine Xeloda R 54 advanced metastatic prostate 54 5 Fluorouracil 54 nilotinib Tasigna 54 Allovectin 7 54 folinic acid 54 VAPRISOL 54 MDS AML 53 Clofarabine 53 bicalutamide 53 protease inhibitors 53 vinca alkaloid 53 hepatitis C genotype 53 β blockers 53 chemo immunotherapy 53 taxotere 53 ZACTIMA 53 nelfinavir 53 HCV RESPOND 2 53 tumor recurrence 53 EFAPROXYN 53 CR# vcMMAE 53 obatoclax 53 patients evaluable 53 CD# antibody [001] 53 GvHD 53 immunotherapies 53 Rituxan rituximab 53 Marqibo 53 PROLARIS 53 belinostat 53 elotuzumab 53 levodopa therapy 53 multiple myeloma MM 53 forodesine 53 taxol 53 TMP SMX 53 androgen suppression therapy 53 antiemetics 53 ganciclovir 53 entinostat 53 Pegasys peginterferon alfa 2a 53 tumor malignancies 53 lipid lowering therapy 53 hA# 53 fondaparinux 53 lymphadenectomy 53 relapsing remitting multiple sclerosis 53 indolent lymphomas 53 stage IIIA 53 abiraterone 53 breast cancer subtypes 53 aHUS 53 Tamibarotene 53 SCIg 53 Ceplene/IL-2 53 Phase Ib II 53 chronic HCV 53 CAELYX 53 Annamycin 53 sulfadoxine pyrimethamine 53 picoplatin 53 cancer mCRC 53 lumiliximab 53 Vidaza 53 Avastin Tarceva 53 alpha interferons 53 DOXIL ® 53 alefacept 53 iron chelation 53 tenecteplase 53 mealtime insulin 53 fluticasone salmeterol 53 GP IIb IIIa inhibitors 53 therapy 53 LMWH 53 LHRH agonists 53 DFMO 53 anakinra 53 panitumumab Vectibix 53 GISTs 53 Gleevec 53 idiotype vaccine 53 progression TTP 53 teriflunomide 53 etanercept 53 disease progression 53 iniparib BSI 53 platelet reactivity